Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Tiumeq

- PMLiVE

ViiV and Janssen take long-acting HIV regimen into phase III

Cabotegravir and rilpivirine injectable-therapy tipped as future blockbuster

- PMLiVE

AstraZeneca wins EU approvals for Zurampic and Brilique

Its gout drug receives a licence and antiplatelet therapy gains a new indication

- PMLiVE

Harvoni cleared for broader use in hepatitis C

Gilead Sciences’ drug wins US approval for use in liver transplant patients

EU forms mHealth app working group

Tasks it with drafting guidelines for assessing the validity and reliability of the data collected

- PMLiVE

Gilead’s John Martin steps down as chief executive officer

He becomes executive chairman and is replaced as CEO by John Milligan 

- PMLiVE

Merck & Co’s oral hepatitis C therapy approved in US

Fixed-dose combination Zepatier wins a licence from the FDA

EU flag

Baxalta’s rare blood cancer drug Oncaspar approved in Europe

First EU-wide licence for the acute lymphoblastic leukaemia treatment

EU flag

EU launches HIV action plan

Aims to "significantly contribute" to elimination of HIV in EU by 2020

- PMLiVE

UCB wins European approval for epilepsy drug Briviact

Plans first launches within weeks

EU flag

Biogen-Samsung’s Enbrel biosimilar cleared for EU marketing

The companies plan to launch the treatment in the coming weeks

- PMLiVE

ViiV and Janssen plan pivotal trials of monthly HIV treatment

Rilpivirine – cabotegravir combination could provide a monthly option

- PMLiVE

ViiV agrees $1.5bn deal to acquire BMS’ HIV assets

Includes its entire development pipeline - from discovery to preclinical projects

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links